Well dah...ofcourse it looks terible, every other clinical stage biotech looks terrible, the market looks terible. The only question I care about is does the price tell us anything about ARIA's clinical chances of success. I DONT THINK SO. the market is selling biotechs with the risk off trade even though they have little in common with regular cyclicals. The weak justification is they they will need capital in a closed market for capital. If you are smart enough to trade biotechs such as ARIA please do. I am not. I try to make money long term based on RIDA +/- and 534 initiation/partnership, and some hallo effect if they file a third IND. Everything else is for people who think they can time markets.